AstraZeneca Announces Initiation of Tharros - A Phase III Clinical Trial Investigating the Potential of Breztri to Improve Cardiopulmonary Outcomes in People With COPD
March 16, 2024
March 16, 2024
WILMINGTON, Delaware, March 16 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on March 13, 2024:
AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE(R) (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes, including death*, in people with chronic obstructive pulmonary disease (COPD) who also have eleva . . .
AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE(R) (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes, including death*, in people with chronic obstructive pulmonary disease (COPD) who also have eleva . . .